1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Yunnan Baiyao Group Co. Ltd. Class A

Yunnan Baiyao Group Co. Ltd. Class A

SSZSE:000538
52.40
CNY
-0.33
(-0.63%)
3.26EPS
14.64P/E
84.52BMarket Cap
Oct 30Next Earn
Yunnan Baiyao Group Co. Ltd. Class A
SZSE:000538
(Shenzhen Stock Exchange)

Recent

price

52.40

P/E

ratio

14.64

div

yld

5.38%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
6.89
7.74
9.48
10.85
12.92
14.22
15.35
16.68
15.13
16.61
18.32
28.66
23.1
21.88
22.42
23.1
24
Revenue per Share
0.63
0.83
1.09
1.59
1.72
1.9
2
2.16
1.96
2.34
3.09
2.21
1.9
2.29
2.66
2.89
3.24
Basic EPS, GAAP
-0.1
-0.56
0.46
0.18
0.97
1.4
1.95
0.66
0.56
0.74
1.87
3.69
1.75
1.64
2.03
2.31
- -
Free Cash Flow per Basic Share
0.07
0.05
0.08
0.21
0.25
0.4
0.47
0.64
0.11
1.5
2.19
3.89
1.34
1.54
3.33
2.26
2.82
Dividend per Share
3.03
3.81
4.88
6.19
7.67
9.21
10.79
12.37
27.27
21.21
21.28
21.29
21.43
22.19
21.76
22.44
22.96
Book Value per Share
2.94
3.63
4.71
6.03
7.49
9.04
10.62
12.14
26.99
20.89
20.96
20.88
21.02
21.8
21.38
21.83
22.34
Tangible Book Value per Share
1,462
1,461
1,458
1,457
1,456
1,458
1,460
1,458
1,785
1,786
1,788
1,269
1,580
1,788
1,785
1,783
1,785
Basic Weighted Avg Shares
10,075
11,312
13,815
15,815
18,814
20,738
22,411
24,315
27,017
29,665
32,743
36,374
36,488
39,111
40,033
41,187
42,833
Sales/Revenue/Turnover
10.29
11.89
13.11
13.57
13.82
14.59
14.35
14.07
14.22
10.99
13.02
12.44
11.41
9.85
11.92
12.21
12.36
Operating Margin (%)
34
35
72
86
89
122
117
130
141
160
168
348
454
340
311
358
- -
Depreciation Expense
926
1,211
1,583
2,321
2,506
2,771
2,920
3,145
3,494
4,184
5,516
2,805
3,001
4,094
4,749
5,153
5,776
Net Income, GAAP
10.91
13.93
13.52
14.06
14.19
14.3
13.73
13.51
5.85
11.7
18.97
19.65
15.89
14.43
16.14
14.12
13.03
Effective Tax Rate (%)
9.19
10.7
11.46
14.68
13.32
13.36
13.03
12.93
12.93
14.1
16.85
7.71
8.22
10.47
11.86
12.51
13.48
Profit Margin (%)
3,336
4,035
5,414
7,235
10,124
12,227
15,333
17,579
36,669
35,087
33,541
32,786
22,119
23,578
21,292
21,144
21,282
Working Capital
7
7
7
7
903
903
1,801
1,800
4
917
166
260
288
174
193
228
135
LT Debt
4,415
5,555
7,118
9,029
11,295
13,528
15,844
18,143
40,100
38,100
38,344
38,435
38,527
39,905
38,866
40,148
41,048
Total Equity
22.58
23.29
24.43
27.88
22.63
20.11
17.6
16.47
10.78
10.01
13.6
6.78
6.99
10.08
11.89
13.11
13.85
Return on Invested Capital (%)
23.18
24.25
25.13
28.92
24.02
21.4
18.79
17.38
11.51
10.35
14.06
6.96
7.92
9.94
11.75
12.81
13.96
Return on Capital (%)
23.17
24.29
25
28.77
24.8
22.51
20.03
18.63
12.09
10.77
14.52
7.35
7.82
10.45
12.07
13.07
14.13
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
259
105
190
LT Borrowings
87
87
2
LT Finance Leases
142
132
133
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,784
1,784
1,784
Market Capitalization
101,275
97,885
84,521

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
34,035
35,921
34,268
Cash, Cash Equivalents & STI
13,300
14,018
14,321
Accounts Receivable, Net
10,160
11,919
10,183
Inventories
6,231
6,155
6,148
Total Current Liabilities
12,890
13,099
12,986
Payables & Accruals
- -
- -
- -
ST Debt
259
105
190
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.31%
0.95%
3.3%
Free Cash Flow
20.49%
8.53%
13.75%
Net Income, GAAP
9.46%
3.76%
8.51%
Sales/Revenue/Turnover
7.17%
4.77%
2.88%
Total Cash Common Dividend
130.69%
16.65%
-32.17%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,774
9,681
9,460
10,118
40,033
2025
10,841
10,416
- -
10,533
41,187
2026
11,603
10,281
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.95
0.83
0.64
0.24
2.66
2025
1.08
0.95
- -
0.21
2.89
2026
1.14
0.93
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
2.08
0.01
1.23
3.33
2025
- -
1.23
- -
- -
2.26
2026
- -
1.58
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Yunnan Baiyao Group Co., Ltd. (000538.SZ) engages primarily in the research, development, production, and sale of pharmaceuticals and healthcare products with a focus on traditional Chinese medicine. The company offers a diversified portfolio encompassing health products including toothpastes, shampoos, and skincare creams; prescription and over-the-counter drugs such as Yunnan Baiyao aerosol, ointment, capsules, powder, band-aids, and hemostatic agents; medical devices; traditional Chinese medicine resources like herbal raw materials (e.g., Sanqi/Notoginseng); tea products; and medicine distribution services through its commercial arm. Founded in 1902 and headquartered in Kunming, Yunnan Province, China, the company operates across four major business segments—pharmaceuticals, health products, traditional Chinese medicine resources, and pharmaceutical distribution—with geographic reach extending to China, Southeast Asia, Europe, the United States, Japan, and other international markets. In recent developments, Yunnan Baiyao completed the full acquisition of Juyao Hall in August 2025 for RMB 6.6 billion in cash, bolstering its capabilities in Chinese herbal decoction pieces and granule formulations with complementary northern China sales coverage and performance commitments projecting net profits of RMB 66 million in 2025. The company underwent major organizational restructuring since 2023 alongside senior management changes, launched 50 new products contributing to 12% year-over-year sales growth, announced expansion into 10 additional countries targeting $100 million in new revenue by 2025, and formed a strategic partnership with Peking University Hospital of Stomatology to advance oral health initiatives. Its Smart Factory earned recognition from the World Economic Forum's Global Lighthouse Network in September 2025, underscoring advancements in intelligent manufacturing.